CMF7 ADA and AACE Guidelines for Individualized Diabetes Management

Program: Case Management Forums
Clinical Session
Sunday, April 3, 2016: 3:30 PM-4:15 PM
Room 210 (BCEC)
Speakers:
Lawrence Blonde, MD, FACP, FACE, Ochsner Medical Center, New Orleans, LA and Silvio E Inzucchi, MD, Yale School of Medicine, New Haven, CT

Disclosures:
LB: Principal Investigator, Eli Lilly & Company, Investigator, Novo Nordisk, Investigator, Sanofi, Speaker, Astra Zeneca, Speaker, Jansen Pharmaceuticals, Consultant, Merck & Co., Consultant, GlaxoSmithKline, Consultant, Intarcia. SEI: Committee Member, Novo Nordisk, Advisory Group Member, Jansen Pharmaceuticals, Advisory Group Member, Merck & Co., Speaker, Astra Zeneca, Coinvestigator, Takeda, Steering Committee Member, Boehringer Ingelheim.
See more of: Case Management Forums

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire